Folic acid in stroke prevention in countries without mandatory folic acid food fortification: A meta-analysis of randomized controlled trials

Journal of Stroke

Volumn 20, Issue 1, 2018, Pages 99-109

  Hsu, Chia Yu ^a   Chiu, Shao Wen ^a   Hong, Keun Sik ^b   Saver, Jeffrey L ^c   Wu, Yi Ling ^d   Lee, Jiann Der ^a   Lee, Meng ^a   Ovbiagele, Bruce ^e  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b Inje University College of Medicine   (South Korea)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Folic acid; Food; Fortified; Meta analysis; Prevention; Stroke

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID;

ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMPARATIVE EFFECTIVENESS; DIET SUPPLEMENTATION; DRUG EFFICACY; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TREATMENT DURATION;

EID: 85041733991     PISSN: 22876391     EISSN: 22876405     Source Type: Journal    
DOI: 10.5853/jos.2017.01522     Document Type: Article

References (58)

1. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-2022.
2. Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, et al. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases. Z Kardiol 2004;93:439-453.
3. Homocysteine Lowering Trialists’ Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr 2005;82:806-812.
4. Martí-Carvajal AJ, Solà I, Lathyris D. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2015;1:CD006612.
5. Li Y, Huang T, Zheng Y, Muka T, Troup J, Hu FB. Folic acid supplementation and the risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. J Am Heart Assoc 2016;5:e003768.
6. Lee M, Hong KS, Chang SC, Saver JL. Efficacy of homocysteine-lowering therapy with folic acid in stroke prevention: a meta-analysis. Stroke 2010;41:1205-1212.
7. Huo Y, Qin X, Wang J, Sun N, Zeng Q, Xu X, et al. Efficacy of folic acid supplementation in stroke prevention: new insight from a meta-analysis. Int J Clin Pract 2012;66:544-551.
8. Ji Y, Tan S, Xu Y, Chandra A, Shi C, Song B, et al. Vitamin B supplementation, homocysteine levels, and the risk of cerebrovascular disease: a meta-analysis. Neurology 2013;81:1298-1307.
9. Yang Q, Botto LD, Erickson JD, Berry RJ, Sambell C, Johansen H, et al. Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 2006;113:1335-1343.
10. Huo Y, Li J, Qin X, Huang Y, Wang X, Gottesman RF, et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA 2015;313:1325-1335.
11. Kotwal J, Kotwal A, Bhalla S, Singh PK, Nair V. Effectiveness of homocysteine lowering vitamins in prevention of thrombotic tendency at high altitude area: a randomized field trial. Thromb Res 2015;136:758-762.
12. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
13. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Oxford, UK: The Cochrane Collaboration, 2008.
14. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001; 54:1046-1055.
15. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 2008;61:64-75.
16. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (visp) randomized controlled trial. JAMA 2004;291:565-575.
17. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004;15:420-426.
18. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-1577.
19. Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 2007;297:2351-2359.
20. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007;298:1163-1170.
21. Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 2008;299:2027-2036.
22. House AA, Eliasziw M, Cattran DC, Churchill DN, Oliver MJ, Fine A, et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 2010;303:1603-1609.
23. Bostom AG, Carpenter MA, Kusek JW, Levey AS, Hunsicker L, Pfeffer MA, et al. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the folic acid for vascular outcome reduction in transplantation trial. Circulation 2011;123:1763-1770.
24. Lamas GA, Boineau R, Goertz C, Mark DB, Rosenberg Y, Stylianou M, et al. Oral high-dose multivitamins and minerals after myocardial infarction: a randomized trial. Ann Intern Med 2013;159:797-805.
25. Mark SD, Wang WFraumeni JF Jr, Li JY, Taylor PR, Wang GQ, et al. Lowered risks of hypertension and cerebrovascular disease after vitamin/mineral supplementation: the Linxian Nutrition Intervention Trial. Am J Epidemiol 1996;143:658-664.
26. Liem AH, van Boven AJ, Veeger NJ, Withagen AJ, Robles de Medina RM, Tijssen JG, et al. Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction: a randomised pilot trial. Int J Cardiol 2004;93:175-179.
27. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, van Veldhuisen DJ. Secondary prevention with folic acid: results of the Goes extension study. Heart 2005;91:1213-1214.
28. Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-1588.
29. Righetti M, Serbelloni P, Milani S, Ferrario G. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif 2006;24:379-386.
30. Zoungas S, McGrath BP, Branley P, Kerr PG, Muske C, Wolfe R, et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (asfast) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol 2006;47:1108-1116.
31. Ebbing M, Bleie Ø, Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA 2008;300:795-804.
32. Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S, et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ 2010;341:c6273.
33. VITATOPS Trial Study Group. B vitamins in patients with recent transient ischaemic attack or stroke in the vitamins to Prevent Stroke (vitatops) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol 2010;9:855-865.
34. Heinz J, Kropf S, Domröse U, Westphal S, Borucki K, Luley C, et al. B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial. Circulation 2010;121:1432-1438.
35. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, Armitage JM, Bowman L, Clarke RJ, Wallendszus K, Bulbulia R, et al. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA 2010;303:2486-2494.
36. Spence JD, House AA, Eliasziw M. B-vitamin therapy for diabetic nephropathy: reply. JAMA 2010;304:636-637.
37. Spence JD, Bang H, Chambless LE, Stampfer MJ. Vitamin intervention for stroke prevention trial: an efficacy analysis. Stroke 2005;36:2404-2409.
38. Spence JD, Yi Q, Hankey GJ. B vitamins in stroke prevention: time to reconsider. Lancet Neurol 2017;16:750-760.
39. Spence JD, Stampfer MJ. Understanding the complexity of homocysteine lowering with vitamins: the potential role of subgroup analyses. JAMA 2011;306:2610-2611.
40. Xu X, Qin X, Li Y, Sun D, Wang J, Liang M, et al. Efficacy of folic acid therapy on the progression of chronic kidney disease: the renal substudy of the China stroke primary prevention trial. JAMA Intern Med 2016;176:1443-1450.
41. Robertson J, Iemolo F, Stabler SP, Allen RH, Spence JD. Vitamin B12, homocysteine and carotid plaque in the era of folic acid fortification of enriched cereal grain products. CMAJ 2005;172:1569-1573.
42. Spence JD. Metabolic vitamin B12 deficiency: a missed oppor tunity to prevent dementia and stroke. Nutr Res 2016;36:109-116.
43. Iso H, Moriyama Y, Sato S, Kitamura A, Tanigawa T, Yamagi-shi K, et al. Serum total homocysteine concentrations and risk of stroke and its subtypes in Japanese. Circulation 2004;109:2766-2772.
44. Perini F, Galloni E, Bolgan I, Bader G, Ruffini R, Arzenton E, et al. Elevated plasma homocysteine in acute stroke was not associated with severity and outcome: stronger association with small artery disease. Neurol Sci 2005;26:310-318.
45. Khan U, Crossley C, Kalra L, Rudd A, Wolfe CD, Collinson P, et al. Homocysteine and its relationship to stroke subtypes in a uk black population: the south London ethnicity and stroke study. Stroke 2008;39:2943-2949.
46. Ma Y, Zhao X, Zhang W, Liu L, Wang Y, Fang R, et al. Homocysteine and ischemic stroke subtype: a relationship study in Chinese patients. Neurol Res 2010;32:636-641.
47. Vermeer SE, van Dijk EJ, Koudstaal PJ, Oudkerk M, Hofman A, Clarke R, et al. Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam Scan Study. Ann Neurol 2002;51:285-289.
48. Seshadri S, Wolf PA, Beiser AS, Selhub J, Au R, Jacques PF, et al. Association of plasma total homocysteine levels with subclinical brain injury: cerebral volumes, white matter hyperintensity, and silent brain infarcts at volumetric magnetic resonance imaging in the Framingham Offspring Study. Arch Neurol 2008;65:642-649.
49. Tseng YL, Chang YY, Liu JS, Su CS, Lai SL, Lan MY. Association of plasma homocysteine concentration with cerebral white matter hyperintensity on magnetic resonance images in stroke patients. J Neurol Sci 2009;284:36-39.
50. Kloppenborg RP, Nederkoorn PJ, van der Graaf Y, Geerlings MI. Homocysteine and cerebral small vessel disease in patients with symptomatic atherosclerotic disease. The SMART-MR study. Atherosclerosis 2011;216:461-466.
51. Xu C, Wu Y, Liu G, Liu X, Wang F, Yu J. Relationship between homocysteine level and diabetic retinopathy: a systematic review and meta-analysis. Diagn Pathol 2014;9:167.
52. Xie D, Yuan Y, Guo J, Yang S, Xu X, Wang Q, et al. Hyperhomocysteinemia predicts renal function decline: a prospective study in hypertensive adults. Sci Rep 2015;5:16268.
53. Cavalieri M, Schmidt R, Chen C, Mok V, de Freitas GR, Song S, et al. B vitamins and magnetic resonance imaging-detected ischemic brain lesions in patients with recent transient ischemic attack or stroke: the vitamins to Prevent Stroke (VITATOPS) MRI-substudy. Stroke 2012;43:3266-3270.
54. Vermeulen EG, Stehouwer CD, Valk J, van der Knaap M, van den Berg M, Twisk JW, et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B on cerebrovascular atherosclerosis and white matter abnormalities as determined by MRA and MRI: a placebo-controlled, randomized trial. Eur J Clin Invest 2004;34:256-261.
55. Crider KS, Bailey LB, Berry RJ. Folic acid food fortification—its history, effect, concerns, and future directions. Nutrients 2011;3:370-384.
56. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999;340:1449- 1454.
57. Tighe P, Ward M, McNulty H, Finnegan O, Dunne A, Strain J, et al. A dose-finding trial of the effect of long-term folic acid intervention: implications for food fortification policy. Am J Clin Nutr 2011;93:11-18.
58. Kelly PJ, Shih VE, Kistler JP, Barron M, Lee H, Mandell R, et al. Low vitamin B6 but not homocyst(e)ine is associated with increased risk of stroke and transient ischemic attack in the era of folic acid grain fortification. Stroke 2003;34:e51-e54.